Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05332262 · ClinicalTrials.gov registry record

A Precision Medicine Approach to Identify Patients Undergoing Elective PCI at Risk of Peri-PCI Myocardial Infarction

A clinical trial of Coronary Artery Disease, sponsored by University of Florida.

Recruiting
Registry status
500
Enrollment target
1
Study location

NCT05332262 is a study of Coronary Artery Disease that is actively recruiting participants, run by University of Florida. The registered enrollment target is 500 participants, below the 1,285-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05332262, a study of Coronary Artery Disease, is actively recruiting participants, sponsored by University of Florida.

RECRUITING
Registry status
500 participants
Enrollment target
1
Study location

Study Summary

Despite the relative safety of PCI with new generation stents, peri-PCI thrombotic complications, including myocardial infarction and myocardial injury, are common in elective PCI, occurring in up to 30% of patients. Importantly, these events are associated with poor prognosis. The risk of peri-PCI myocardial infarction/myocardial injury has been in part attributed to HPR. The aim of this study is to prospectively validate the accuracy of the ABCD-GENE score in identifying stable CAD patients undergoing elective PCI treated with standard of care clopidogrel who are at risk of peri-PCI myocardial infarction/myocardial injury. This investigation will be a prospective cohort study conducted in a population of patients (n=500) with stable CAD undergoing elective PCI treated with standard of care clopidogrel. By integrating genetic data with clinical variables, patients will be stratified into 2 cohorts based on their ABCD-GENE score (using a cut-off of 10). Assessments to define HPR status and myocardial infarction/myocardial injury will be performed post-PCI.

Conditions Studied

Coronary Artery Disease

Interventions

  • DIAGNOSTIC_TEST Assessment of platelet reactivity
  • DIAGNOSTIC_TEST Troponin measurement

Study Locations (1)

Florida

  • University of Florida Jacksonville - Jacksonville

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2022-05-23
Est. Completion 2027-08

Sponsor

University of Florida

1,106 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05332262

The ClinicalTrials.gov registry entry for NCT05332262 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,285-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (61% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which Assessment of platelet reactivity is the first listed.

NCT05332262 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT05332262 about?

NCT05332262 is a clinical study titled "A Precision Medicine Approach to Identify Patients Undergoing Elective PCI at Risk of Peri-PCI Myocardial Infarction". Despite the relative safety of PCI with new generation stents, peri-PCI thrombotic complications, including myocardial infarction and myocardial injury, are common in elective PCI, occurring in up to 30% of patients. Importantly, these events are associated with poor prognosis. The risk of peri-PCI ...

What is the current status of trial NCT05332262?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2022-05-23. Estimated completion is 2027-08.

What conditions does trial NCT05332262 study?

This clinical trial studies the following conditions: Coronary Artery Disease.

What interventions are being tested in trial NCT05332262?

The interventions under investigation include: Assessment of platelet reactivity (DIAGNOSTIC_TEST), Troponin measurement (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05332262?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05332262 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Coronary Artery Disease

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.